Episode
Targeting Cancer With Precision: Inside Antibody Drug Conjugates
- Podcast
- Moving Medicine Forward
- Published
- Mar 26, 2026
- Duration seconds
- 809
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/moving-medicine-forward-6832193/episodes/targeting-cancer-with-precision-inside-antibody-drug-conjugates/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/moving-medicine-forward-6832193/targeting-cancer-with-precision-inside-antibody-drug-conjugates.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Antibody drug conjugates (ADCs) are transforming cancer research — but how do they actually work, and what does it take to bring them safely to patients? In this episode of Moving Medicine Forward , we speak with scientist Lidia Blasco about the science and promise of antibody drug conjugates (ADCs) in cancer research. Lidia shares her journey from pharmacy and forensic analysis to oncology research, explaining in clear terms how ADCs work, why they’re transforming treatment, and what it means to develop them responsibly. The conversation also highlights the human side of clinical trials and the patients who make medical progress possible. 01:18 – Lidia Blasco’s background and path into ADC research 02:30 – Balancing PhD work with hands‑on industry lab experience 03:40 – Antibody drug conjugates explained simply 04:45 – Why ADCs are a promising cancer treatment approach 06:26 – The goal and impact of Lidia’s PhD research platform 07:30 – Improving dosing decisions and patient safety in clinical trials 08:06 – Emerging trends and innovations in ADC development 09:27 – Advice for those considering a career in oncology research 10:43 – Honoring the patients behind the research samples 12:53 – Closing reflections and final takeaways